Immuron - Grande!!!!

[mimmo6]

Societa' australiana, quotata su ASX e NASDAQ.

Immuron Limited - American Depositary Shares
(NASDAQ:IMRN)

Immuron Limited
(ASX:IMC)

Mkt cap 38.08M

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.
_____________-



Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) flag-ship product Travelan® has achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018, representing a 250% increase on the same period last year.

Travelan had $579,000 in sales in the Australian market, representing a 27% increase on the same period last year.
New clinical study of IMM-529

Immuron is also developing and commercializing other oral immunetherapeutics for the treatment of gut related diseases.

Last month, the company enrolled the first patients into its first-in-human IMM-529 clinical study for the treatment of clostridium difficile infection (CDI).

Most commonly affecting older adults after use of antibiotic medications, CDI can cause symptoms that range from diarrhea to life-threatening gut inflammation.

IMM-529 uses a combination of polyclonal antibodies to target and neutralise the three main virulence factors of CDI without negatively impacting the microbiome.
Clostridium-difficile infection is a multi-billion dollar market

According to the Centers for Disease Control and Prevention (CDC), clostridium-difficile infects more than 450,000 patients causing over 29,000 deaths per year in the U.S alone.

There is a high likelihood for recurrence of symptoms, which nearly triples the healthcare costs per patient, resulting in annual healthcare costs of nearly $4.5 billion.

 

[mimmo6]

Google Traduttore

 

[mimmo6]

Immuron’s Travelan successful in US Department of Defense testing
By
Lorna Nicholas -
January 30, 2018


Microbiome biopharmaceutical company Immuron (ASX: IMC) reported its commercially available Travelan had performed well during United States Department of Defense testing, with the product reacting to 180 infectious bacterial strains from South East Asia.

Travelan contains a rich antibodies and is marketed at travellers for prevention of travellers diarrhoea, Delhi Belly, Montezuma’s Revenge, Tourist Trot, Rangoon Runs that can be contracted from eating or drinking contaminated food or water, particularly in developing countries.

The US Department of Defense commissioned the study which was carried out in Bangkok, Thailand. The study investigated the immune-reactivity of Travelan on Campylobacter, Enterotoxigenic Escherichia coli and Shigella bacteria.

Clinical isolates taken from infected patients across South East Asia between 1993 and 2016 were tested with Travelan. Researchers measured the impact of Travelan antibodies on the infectious bacterial strains.

The product was also found to react to 180 clinical isolates from the infected individuals.

According to Immuron, Travelan product’s ability to bind and neutralise bacteria, highlights its effectiveness against potentially harmful bacteria.

“We are pleased to see that Travelan, a product that has achieved significant sales growth, has proven its reactivity to a multitude of clinically relevant bacterium strains within South East Asia,” Immuron chief executive officer Dr Jerry Kanellos said.

Dr Kanellos added this was the first of three research projects to be undertaken with the US Department of Defense, with further results expected in the coming months.

“Travelan’s reactivity to various forms of these infectious diseases makes it a valuable asset to foreign government officials looking to protect employees stationed in these regions, as well as consumers who want to preserve their health while travelling abroad,” Dr Kanellos said.

He pointed out that government and international company uptake of Travelan would pose a “significant” revenue opportunity for Immuron in addition to consumer sales.

The US Department of Defense is currently focused on providing its employees with a prophylactic treatment that can prevent diseases caused by infectious bacteria while travelling, with Shigella, alone estimated to cause 165 million disease cases globally and 600,000 deaths a year.

Immuron’s share price shot up in intraday trade before settling up 21% at A$0.28 by late afternoon.

 

[coffeman]

se ho capito bene è un prodotto contro la ca.ga.rel.la?

 

[mimmo6]

se ho capito bene è un prodotto contro la ca.ga.rel.la?

 

[coffeman]

[/QUO

provato col limone?